Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model

Diana L. Castillo-Carranza, Marcos J. Guerrero-Muñoz, Urmi Sengupta, Caterina M. Hernandez, Alan D.T. Barrett, Kelly Dineley, Rakez Kayed

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

In Alzheimer’s disease (AD), the pathological accumulation of tau appears to be a downstream effect of amyloid β; protein (Aβ;). However, the relationship between these two proteins and memory loss is unclear. In this study, we evaluated the specific removal of pathological tau oligomers in aged Tg2576 mice by passive immunotherapy using tau oligomer-specific monoclonal antibody. Removal of tau oligomers reversed memory deficits and accelerated plaque deposition in the brain. Surprisingly, Aβ*56 levels decreased, suggesting a link between tau and Aβ oligomers in the promotion of cognitive decline. The results suggest that tau oligomerization is not only a consequence of Aβ pathology but also a critical mediator of the toxic effects observed afterward in AD. Overall, these findings support the potential of tau oligomers as a therapeutic target for AD.

Original languageEnglish (US)
Pages (from-to)4857-4868
Number of pages12
JournalJournal of Neuroscience
Volume35
Issue number12
DOIs
StatePublished - Jan 1 2015

Fingerprint

Amyloid
Immunotherapy
Alzheimer Disease
Memory Disorders
Pathology
Passive Immunization
Poisons
Staphylococcal Protein A
Monoclonal Antibodies
Brain
Proteins
Therapeutics

Keywords

  • Alzheimer’s disease
  • Aβ*56
  • Immunotherapy
  • Tau oligomers
  • Tg2576

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Sengupta, U., Hernandez, C. M., Barrett, A. D. T., Dineley, K., & Kayed, R. (2015). Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model. Journal of Neuroscience, 35(12), 4857-4868. https://doi.org/10.1523/JNEUROSCI.4989-14.2015

Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model. / Castillo-Carranza, Diana L.; Guerrero-Muñoz, Marcos J.; Sengupta, Urmi; Hernandez, Caterina M.; Barrett, Alan D.T.; Dineley, Kelly; Kayed, Rakez.

In: Journal of Neuroscience, Vol. 35, No. 12, 01.01.2015, p. 4857-4868.

Research output: Contribution to journalArticle

Castillo-Carranza, DL, Guerrero-Muñoz, MJ, Sengupta, U, Hernandez, CM, Barrett, ADT, Dineley, K & Kayed, R 2015, 'Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model', Journal of Neuroscience, vol. 35, no. 12, pp. 4857-4868. https://doi.org/10.1523/JNEUROSCI.4989-14.2015
Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Hernandez CM, Barrett ADT, Dineley K et al. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model. Journal of Neuroscience. 2015 Jan 1;35(12):4857-4868. https://doi.org/10.1523/JNEUROSCI.4989-14.2015
Castillo-Carranza, Diana L. ; Guerrero-Muñoz, Marcos J. ; Sengupta, Urmi ; Hernandez, Caterina M. ; Barrett, Alan D.T. ; Dineley, Kelly ; Kayed, Rakez. / Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model. In: Journal of Neuroscience. 2015 ; Vol. 35, No. 12. pp. 4857-4868.
@article{1c0c1d8f10c64f3a8fdd1eacd941a7fa,
title = "Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model",
abstract = "In Alzheimer’s disease (AD), the pathological accumulation of tau appears to be a downstream effect of amyloid β; protein (Aβ;). However, the relationship between these two proteins and memory loss is unclear. In this study, we evaluated the specific removal of pathological tau oligomers in aged Tg2576 mice by passive immunotherapy using tau oligomer-specific monoclonal antibody. Removal of tau oligomers reversed memory deficits and accelerated plaque deposition in the brain. Surprisingly, Aβ*56 levels decreased, suggesting a link between tau and Aβ oligomers in the promotion of cognitive decline. The results suggest that tau oligomerization is not only a consequence of Aβ pathology but also a critical mediator of the toxic effects observed afterward in AD. Overall, these findings support the potential of tau oligomers as a therapeutic target for AD.",
keywords = "Alzheimer’s disease, Aβ*56, Immunotherapy, Tau oligomers, Tg2576",
author = "Castillo-Carranza, {Diana L.} and Guerrero-Mu{\~n}oz, {Marcos J.} and Urmi Sengupta and Hernandez, {Caterina M.} and Barrett, {Alan D.T.} and Kelly Dineley and Rakez Kayed",
year = "2015",
month = "1",
day = "1",
doi = "10.1523/JNEUROSCI.4989-14.2015",
language = "English (US)",
volume = "35",
pages = "4857--4868",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "12",

}

TY - JOUR

T1 - Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an alzheimer’s disease mouse model

AU - Castillo-Carranza, Diana L.

AU - Guerrero-Muñoz, Marcos J.

AU - Sengupta, Urmi

AU - Hernandez, Caterina M.

AU - Barrett, Alan D.T.

AU - Dineley, Kelly

AU - Kayed, Rakez

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In Alzheimer’s disease (AD), the pathological accumulation of tau appears to be a downstream effect of amyloid β; protein (Aβ;). However, the relationship between these two proteins and memory loss is unclear. In this study, we evaluated the specific removal of pathological tau oligomers in aged Tg2576 mice by passive immunotherapy using tau oligomer-specific monoclonal antibody. Removal of tau oligomers reversed memory deficits and accelerated plaque deposition in the brain. Surprisingly, Aβ*56 levels decreased, suggesting a link between tau and Aβ oligomers in the promotion of cognitive decline. The results suggest that tau oligomerization is not only a consequence of Aβ pathology but also a critical mediator of the toxic effects observed afterward in AD. Overall, these findings support the potential of tau oligomers as a therapeutic target for AD.

AB - In Alzheimer’s disease (AD), the pathological accumulation of tau appears to be a downstream effect of amyloid β; protein (Aβ;). However, the relationship between these two proteins and memory loss is unclear. In this study, we evaluated the specific removal of pathological tau oligomers in aged Tg2576 mice by passive immunotherapy using tau oligomer-specific monoclonal antibody. Removal of tau oligomers reversed memory deficits and accelerated plaque deposition in the brain. Surprisingly, Aβ*56 levels decreased, suggesting a link between tau and Aβ oligomers in the promotion of cognitive decline. The results suggest that tau oligomerization is not only a consequence of Aβ pathology but also a critical mediator of the toxic effects observed afterward in AD. Overall, these findings support the potential of tau oligomers as a therapeutic target for AD.

KW - Alzheimer’s disease

KW - Aβ56

KW - Immunotherapy

KW - Tau oligomers

KW - Tg2576

UR - http://www.scopus.com/inward/record.url?scp=84925845438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925845438&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.4989-14.2015

DO - 10.1523/JNEUROSCI.4989-14.2015

M3 - Article

VL - 35

SP - 4857

EP - 4868

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 12

ER -